Skip to main content
SpringerLink
Log in

Isavuconazole cost saving as first-line treatment of IA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Astellas Pharma Global Development, Inc.

Reference

  • Harrington R, et al. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Advances in Therapy : 2 Dec 2016. Available from: URL: http://doi.org/10.1007/s12325-016-0443-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Isavuconazole cost saving as first-line treatment of IA. PharmacoEcon Outcomes News 768, 19 (2016). https://doi.org/10.1007/s40274-016-3617-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3617-9

Search

Navigation